Arch Venture Partners, fresh from co-founding the massively financed Seattle biotech startup Juno Therapeutics, has closed on a new venture capital fund topping $400 million. The company, with offices ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback